A central strategy for healthcare surge control would be to provide remote effective monitoring of patients with Covid-19 and their follow-up. Telemedicine not only allows patients to be carefully screened but also enables a patient-centred system and being conducive to self-quarantine. In addition, patients, clinicians and the community are protected from exposure \[[@bib1]\].

Patients with cancer during or after treatment have an increased risk of complication and death related to Covid-19 contagion \[[@bib2],[@bib3]\].

In this report, physicians in Gustave Roussy Cancer Institute (GRCI), France, a leading European tertiary cancer centre, describe the use of telemedicine for monitoring and optimising referral of Covid-19--positive patients with cancer. The CAPRI telemedicine programme has been set up to monitor patients with cancer undergoing oral therapy \[[@bib4]\] ([Fig. 1](#fig1){ref-type="fig"} ). Faced with the Covid-19 crisis, we adapted the system accordingly in a period of two weeks, also drawing inspiration from another programme \[[@bib5]\].Fig. 1CAPRI process for monitoring patients with cancer. PRO, patient reported outcome.Fig. 1

Capri Covid-19 consists of a Web application for patients and a telephone platform with a dedicated call number, the entire procedure being managed by four GR nurse navigators (NNs). It can allow NNs and patients to communicate 24/7 (from 8:30 am to 6 pm; outside the centre, the patient must contact the emergency service) through secure messaging (i.e. the platform complies with the French regulation on data protection). The Web application allows patients to fill in questions specific to Covid-19 based on a patient-reported outcome approach, which has demonstrated its added value in an oncology context \[[@bib6]\]. Finally, the application provides NNs with a complete panel to view individual electronic patient medical records.

If Covid-19 is suspected, either when the patient comes to the hospital (emergency department or consultation, in which case, the patient is asked to return home while the test results are pending) or at home, the patient is tested. Covid-19--positive patients are included in the CAPRI programme after having provided informed consent and follow a 4-phase remote monitoring strategy (see [Fig. 2](#fig2){ref-type="fig"} ).Fig. 2Algorithm for remote monitoring of Covid-19--positive patients with cancer. NN = nurse navigator; GP = general practitioner; MO = medical oncologist; MD = medical doctor.Fig. 2

1. Initial assessment {#sec1}
=====================

The NN calls each patient to assess his/her specific cancer concerns (e.g. medical prescriptions), comorbidities and social conditions (isolation and ability to acquire personal needs during the confinement period). In addition, information on the programme is given when the individual account is created, following the guidelines provided by the French authorities (<https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr> = 779). Finally, the patient is offered to choose between two monitoring modes: either by phone or by completing an application form (Web or smartphone).

2. Follow-up {#sec2}
============

This is based on six questions the patients were asked: (i) fever ≥38.3° (100.94° F); (ii) appearance or worsening of respiratory discomfort since the last assessment (LA); (iii) appearance or worsening of a cough since the LA; (iv) drowsiness; (v) any new symptoms since the LA (e.g. muscle aches, headaches) and (vi) appearance or worsening of diarrhoea since the LA. The data are reported following the application twice a day, whereas the data are reported daily in the case of a telephone follow-up.

3. Patient orientation decision {#sec3}
===============================

The system generates alerts if one of the six aforementioned questions is answered positively or if the patient has not responded for more than 24 h. The alert is automatically generated via the application or during daily NN phone calls. In this case, the NN contacts the emergency department manager to organise the patient\'s arrival to the emergency room or the Covid-19 ward directly.

4. Evaluation {#sec4}
=============

A longitudinal assessment is organised, based on five indicators: hospital admissions, emergency visits, access to the intensive care unit after a Covid-19 complication, deaths after a Covid-19 complication and recoveries. These indicators provide a real-time reading of the evolution of the epidemic and will then allow the impact of this intervention to be assessed.

To date, more than hundred patients have been enrolled in the ongoing programme. Our experience shows that Covid-19 crisis is a clinical, epidemiological and organisational issue to overcome. Although telemonitoring cannot solve every problem, it is well suited to the context of Covid-19, and organisations that have already invested in telemedicine are well positioned to expand them and ensure that patients with Covid-19 receive the appropriate care. This decision tree allows not only a collection of data but also a secured organisational process for patient orientation and an optimal physician medical time. Our experience could help other cancer centres, or even healthcare organisations, to implement a rapid effective programme with healthcare professionals monitoring patients at distance while being less exposed. Gustave Roussy Cancer Institute should provide for free the Capri Covid app worldwide to help Covid-infected patients with cancer.

Conflict of interest statement
==============================

F.S. reports personal fees from 10.13039/100008129Helsinn, personal fees from 10.13039/100009947MSD, personal fees from 10.13039/100004337Roche, personal fees from 10.13039/100002429Amgen, personal fees from 10.13039/100013226Pierre Fabre Oncology, personal fees from 10.13039/100004319Pfizer, personal fees from 10.13039/100014470Mundipharma, personal fees from Mylan and personal fees from 10.13039/501100008271Leo Pharma, outside the submitted work; E.M. has no disclosure to declare. O.M. reports personal fees from 10.13039/100002429Amgen, 10.13039/100004325AstraZeneca, 10.13039/100004326Bayer, Blueprint Medicines, 10.13039/100002491Bristol-Myers Squibb, 10.13039/100004312Eli Lilly, Incyte, 10.13039/501100014382Ipsen, 10.13039/501100003554Lundbeck, 10.13039/100009947MSD, 10.13039/100004336Novartis, 10.13039/100004319Pfizer, 10.13039/100004337Roche, 10.13039/501100011725Servier and 10.13039/501100006484Vifor Pharma and other fees from Amplitude Surgical, 10.13039/501100014382Ipsen and Transgene, outside the submitted work; F.A. has no disclosure to declare. F.B. reports personal fees from 10.13039/100004325AstraZeneca, 10.13039/100004326Bayer, 10.13039/100002491Bristol-Myers Squibb, 10.13039/100001003Boehringer Ingelheim, 10.13039/100004312Eli Lilly Oncology, 10.13039/100007013F. Hoffmann-La Roche Ltd, 10.13039/100004336Novartis, 10.13039/100004334Merck, 10.13039/100009947MSD, 10.13039/100013226Pierre Fabre, 10.13039/100004319Pfizer and 10.13039/100007449Takeda, outside the submitted work; J.-C.S. reports feesconsultancy fees from 10.13039/100004325AstraZeneca, 10.13039/100013870Astex, 10.13039/100014487Clovis, 10.13039/100004330GSK, GamaMabs, 10.13039/501100014062Lilly, 10.13039/100009947MSD, Mission Therapeutics, Merus, 10.13039/100004319Pfizer, 10.13039/501100013119PharmaMar, 10.13039/100013226Pierre Fabre, 10.13039/100004337Roche-10.13039/100004328Genentech, 10.13039/100004339Sanofi, 10.13039/501100011725Servier, Symphogen and 10.13039/100007449Takeda, is a full-time employee for AstraZeneca between September 2017 and December 2019, reports other fees from the shareholder Gritstone, during the conduct of the study, and reports personal fees from null, outside the submitted work.

The authors are grateful to Richard Medeiros, Medical Editor from Medical Editing International.
